Entereg (alvimopan)
/ Merck (MSD)
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
151
Go to page
1
2
3
4
5
6
7
March 13, 2026
Alvimopan in patients undergoing radical cystectomy and urinary diversion on a standardized enhanced recovery after surgery protocol: a randomized, double-blind, placebo-controlled trial
(AUA 2026)
- No abstract available
Clinical • Surgery • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer
March 07, 2026
Gastrointestinal Recovery After Radical Cystectomy: Coffee Or Entereg For Enhanced Recovery (GI-COFEE) Trial
(AUA 2026)
- No abstract available
Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer
February 16, 2026
Rapid discovery of repurposed drugs targeting SARS-CoV-2 spike HR1 by DNA-encoded library screening.
(PubMed, Bioorg Chem)
- "Hits including Rabeprazole-related compound E (Rab RCE), Omeprazole, Alvimopan, and Olmesartan were characterized. Mechanistically, Rabeprazole competitively occupies the HR2-binding groove on HR1, blocking fusion. Our findings identify HR1-targeting molecules like Rabeprazole as promising leads for broad-spectrum coronaviral fusion inhibitors."
Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
January 09, 2026
Perioperative Outcomes in Simple Cystectomy for Neurogenic Lower Urinary Tract Dysfunction: A Comparison of Surgical Approach, Surgical Teams, and Alvimopan Use.
(PubMed, Int Neurourol J)
- "NLUTD patients undergoing simple cystectomy represent a distinct surgical cohort. While multiple-surgeon procedures resulted in greater blood loss, they did not affect other perioperative outcomes. Additionally, alvimopan did not significantly improve bowel function recovery or reduce postoperative ileus, likely due to underlying neurogenic bowel dysfunction."
Journal • CNS Disorders • Gastrointestinal Disorder • Inflammatory Bowel Disease • Orthopedics
December 14, 2025
Evaluation of the use and outcomes of alvimopan in bowel resection at Geisinger
(ASHP 2025)
- No abstract available
December 14, 2025
Utilization and Cost Evaluation of Alvimopan in Surgical Patients at a Community Hospital
(ASHP 2025)
- No abstract available
Clinical
August 28, 2025
Multidisciplinary Postoperative Ileus Management: A Narrative Review.
(PubMed, Medicina (Kaunas))
- "Adjuvant interventions such as alvimopan, caffeine, and chewing gum have demonstrated efficacy in modulating the neurogenic and inflammatory components of postoperative ileus. Minimally invasive approaches, comprehensive perioperative management, and adjuvant therapies hold promise for prevention. Current management relies heavily on supportive care, underscoring the need for research into the underlying neurogenic and inflammatory mechanisms to guide the development of targeted treatments."
Journal • Review • Inflammation
August 21, 2025
Alvimopan as a Rescue Treatment of Postoperative Ileus
(clinicaltrials.gov)
- P4 | N=65 | Completed | Sponsor: Scott Steele | Recruiting ➔ Completed
Trial completion
August 10, 2025
Perioperative Naloxegol use in prevention of post-operative ileus in open radical cystectomy
(UAA 2025)
- "Among these, Alvimopan is well-studied and has demonstrated reductions in postoperative ileus, length of hospital stay (LOS), and associated healthcare costs, particularly in procedures such as radical cystoprostatectomy. In this retrospective cohort, perioperative Naloxegol use did not confer a measurable benefit in accelerating gastrointestinal recovery following open radical cystectomy. Despite similar baseline characteristics, Naloxegol was associated with a significantly longer hospital stay and showed no reduction in time to flatus, bowel motion, resumption of diet or complication rate. These findings question the routine use of Naloxegol in this setting and underscore the need for prospective studies to better define its role in enhanced recovery protocols."
May 22, 2025
Ileus After Colectomy in the Modern Era: A Population-Based Analysis.
(PubMed, Dis Colon Rectum)
- "The low observed rate of ileus may reflect the modern era of enhanced recovery and minimally invasive colectomy. Total colectomy is associated with high rate of ileus compared to partial colectomy. Increased implementation of minimally invasive surgery, perioperative alvimopan, and early ambulation might further reduce ileus rates. See Video Abstract."
Journal • Chronic Obstructive Pulmonary Disease • Gastrointestinal Disorder • Immunology • Obstructive Sleep Apnea • Pulmonary Disease • Respiratory Diseases • Sleep Apnea • Sleep Disorder
January 21, 2025
A Prospective Randomized Controlled Trial of the Effectiveness of Alvimopan as a Rescue Treatment of Postoperative Ileus Following Colorectal Surgery
(ASCRS 2025)
- "GI: GastrointestinalTable 1. Patient characteristics and demographics"
Clinical • Surgery • Gastrointestinal Disorder
January 21, 2025
Ileus after colectomy in the modern era: a populationbased analysis
(ASCRS 2025)
- "Total colectomy is associated with a high rate of ileus compared to segmental colectomy. Increased implementation of minimally-invasive surgery, perioperative alvimopan, and early ambulation might further reduce ileus rates.Bivariate Analysis - No Ileus vs IleusOdds Ratios Plot"
Clinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor
January 21, 2025
Ileus after robotic colectomy: A single institution comparison in enhanced recovery
(ASCRS 2025)
- "Alvimopan (p=0.107) and TAP blocks (p=0.257) were not associated with decreased ileus. There was no significant difference in ileus between right and left colectomy (p=0.422).Conclusion/ Postoperative opioids were the only modifiable risk factor for ileus after robotic segmental colectomy. Increasing emphasis on opioid-sparing and other targeted enhanced recovery pathway options should focus on further decreasing the incidence of this vexing postoperative complication.Patient CharacteristicsMultivariable Analysis"
Clinical • Gastrointestinal Disorder • Oncology
May 14, 2025
O-Desmethyltramadol Enhanced Anti-Cancer Efficacy over Tramadol Through Non-μ-Opioid Receptor and Differential Cellular Contexts of Human Breast Cancer Cells.
(PubMed, Int J Mol Sci)
- "The presence of a μ-opioid receptor antagonist Alvimopan did not alter the cytotoxic effects of tramadol and O-desmethyltramadol, indicating a non-opioid receptor-mediated mechanism...Overall, our findings indicated that O-desmethyltramadol exerted potent anti-cancer effects through multiple non-opioid mechanisms, with distinct response from tramadol depending on breast cancer subtype. These findings not only highlight the therapeutic potential of O-desmethyltramadol as a novel adjunct in breast cancer treatment, but also emphasize the need for further investigation into its safety and clinical applicability in oncology."
Journal • Breast Cancer • Oncology • Pain • Solid Tumor • ATF4 • CHAC1 • DDIT3 • IL6
May 09, 2025
ALVIMOPAN ADDITION TO ENHANCED RECOVERY PROGRAM SPEEDS RECOVERY FOLLOWING COLORECTAL SURGERY
(SSAT 2025)
- "The addition of Alvimopan to an existing ERAS protocol in patients undergoing colorectal surgery is associated with significant additional reductions in both LOS and rates of postoperative ileus. Maintaining a high quality of care requires ongoing attention to existing protocols, adaptations where necessary, and continuous outcomes assessment to demonstrate improvement with those adaptations"
Surgery • Cardiovascular • Infectious Disease • Renal Disease
March 08, 2025
ALVIMOPAN ADDITION TO ENHANCED RECOVERY PROGRAM SPEEDS RECOVERY FOLLOWING COLORECTAL SURGERY
(DDW 2025)
- No abstract available
Surgery
March 06, 2025
Underutilization of Alvimopan in Radical Cystectomy: A National Perspective on Benefits and Low Adoption Rates
(AUA 2025)
- "This study provides a nationally representative view of alvimopan use for radical cystectomy, finding that only 39.3% of patients received the medication despite widespread evidence supporting its use. We are able to highlight the median time to alvimopan discontinuation (five doses), suggesting return of bowel function at 60 hours after RC. Further, we associate alvimopan use with decreased antinausea medication need and less GI morbidity to highlight the patient-centered improvement in peri-cystectomy care with alvimopan use."
Bladder Cancer • Gastrointestinal Disorder • Genito-urinary Cancer • Oncology • Solid Tumor
December 01, 2024
Comparing Rates of Postoperative Complications after Colorectal Surgery with Naloxegol versus Alvimopan
(ASHP 2024)
- No abstract available
Surgery
December 01, 2024
Evaluation of Alvimopan in minimally invasive procedures using ERAS
(ASHP 2024)
- No abstract available
December 01, 2024
Evaluation of Adherence to Alvimopan Formulary Restriction Criteria to Improve Patient Safety
(ASHP 2024)
- No abstract available
Adherence • Clinical
December 01, 2024
Effect of Alvimopan and Naloxegol for PostOperative Ileus in a Community Hospital
(ASHP 2024)
- No abstract available
Clinical
December 01, 2024
Alvimopan Medication Use Management Cost Savings Initiative
(ASHP 2024)
- No abstract available
HEOR
November 20, 2024
Postoperative ileus and possibilities of pharmacological intervention.
(PubMed, Rozhl Chir)
- "Postoperative ileus is still recognized as severe complication. Pharmacological treatment options are limited, only a few substances have evident positive impact (neostigmin for treatment and alvimopan - not registered in the Czech Republic for prevention). More evidence is necessary for positive effect of 5-hydroxytryptamine 4 (5HT4) agonists, and the effect of selective COX-2 inhibitors is still controversial."
Journal • Review • Inflammation
November 25, 2024
A Study of Surgical Techniques During Cystectomy
(clinicaltrials.gov)
- P3 | N=530 | Recruiting | Sponsor: Memorial Sloan Kettering Cancer Center
New P3 trial • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor
November 04, 2024
Recovery of gastrointestinal functional after surgery for abdominal tumors: A narrative review.
(PubMed, Medicine (Baltimore))
- "Interventions that can shorten or prevent such ileus include minimally invasive surgery, early enteral nutrition as well as use of chewing gum, laxatives, and alvimopan. Most of these interventions have been integrated into current guidelines for enhanced recovery of gastrointestinal function after surgery. Future high-quality research is needed in order to clarify our understanding of efficacy and safety."
Journal • Review • Surgery • Gastrointestinal Disorder • Infectious Disease • Oncology • Pain
1 to 25
Of
151
Go to page
1
2
3
4
5
6
7